A Phase 2 interventional study of PF-05175157 and Placebo in Type 2 Diabetes Mellitus, sponsored by Pfizer. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-05-02.
Sponsored by Pfizer · Phase 2, Interventional, and Basic science
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 8 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PF-05175157
Drug: Placebo
Tablet, 200 mg, twice daily, 6 weeks
Tablet, 0 mg, twice daily, 2 weeks
Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo
Time frame: Week 0, 4
Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo
Time frame: Weeks 0 and 4
Change from baseline in fasting plasma glucose
Time frame: Weeks 0, 2, 4 and 6
Change from baseline in Glycosylated Hemoglobin (HbA1c)
Time frame: Weeks 0, 4 and 6
Change from baseline in fasting total cholesterol
Time frame: Weeks 0, 4 and 6
Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT)
Time frame: Weeks 0, 4 and 6
Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT)
Time frame: Weeks 0, 4 and 6
Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT)
Time frame: Weeks 0, 4 and 6
Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT
Time frame: Weeks 0, 4 and 6
Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT
Time frame: Weeks 0, 4 and 6
Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR)
Time frame: Weeks 0, 4 and 6
Change from baseline in homeostatic model assessment for β-cell function (HOMA B)
Time frame: Weeks 0, 4 and 6
Change from baseline in low density lipoprotein cholesterol (LDL-C)
Time frame: Weeks 0, 4 and 6
Plasma concentrations for PF-05175157
Time frame: Weeks 2, 4 and 6
Percent change from baseline in body weight
Time frame: Weeks 0, 4 and 6
Change from baseline in high density lipoprotein cholesterol (HDL-C)
Time frame: Weeks 0, 4 and 6
Change from baseline in triglycerides
Time frame: Weeks 0, 4 and 6
Change from baseline in non-HDL cholesterol
Time frame: Weeks 0, 4 and 6
Change from baseline in very low density lipoprotein (VLDL)
Time frame: Weeks 0, 4 and 6
This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer